Mayinglong Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio
Mayinglong Pharmaceutical Group Co Ltd cash flow-to-debt ratio. Mayinglong Pharmaceutical Group Co Ltd (600993) has a Cash Flow-to-Debt Ratio of 0.15x as of September 2025, meaning its operating cash flow of CN¥139.20 Million could theoretically repay 0% of its total liabilities (CN¥909.82 Million) in one year. Check 600993 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Mayinglong Pharmaceutical Group Co Ltd (2003–2025)
Cash flow-to-debt ratio of Mayinglong Pharmaceutical Group Co Ltd from 2003 to 2025. Historical debt coverage capacity for Mayinglong Pharmaceutical Group Co Ltd across 23 annual periods. Check 600993 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Mayinglong Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio by Year (2003–2025)
Mayinglong Pharmaceutical Group Co Ltd cash flow-to-debt ratio by year from 2003 to 2025. Year-by-year debt coverage analysis for Mayinglong Pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see cash efficiency ratio of Mayinglong Pharmaceutical Group Co Ltd.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.65x | CN¥600.44 Million | CN¥921.49 Million | ▲ +28.4% |
| 2024 | 0.51x | CN¥497.61 Million | CN¥980.66 Million | ▼ -19.4% |
| 2023 | 0.63x | CN¥604.07 Million | CN¥959.62 Million | ▲ +164.9% |
| 2022 | 0.24x | CN¥341.85 Million | CN¥1.44 Billion | ▼ -67.7% |
| 2021 | 0.73x | CN¥597.17 Million | CN¥812.72 Million | ▲ +138.9% |
| 2020 | 0.31x | CN¥282.99 Million | CN¥919.89 Million | ▼ -59.3% |
| 2019 | 0.76x | CN¥491.58 Million | CN¥650.49 Million | ▲ +40.9% |
| 2018 | 0.54x | CN¥308.24 Million | CN¥574.67 Million | ▼ -27.3% |
| 2017 | 0.74x | CN¥356.17 Million | CN¥482.99 Million | ▲ +47.7% |
| 2016 | 0.50x | CN¥239.60 Million | CN¥479.88 Million | ▲ +42.9% |
| 2015 | 0.35x | CN¥182.85 Million | CN¥523.31 Million | ▲ +52.3% |
| 2014 | 0.23x | CN¥111.67 Million | CN¥486.89 Million | ▼ -18.6% |
| 2013 | 0.28x | CN¥129.94 Million | CN¥461.22 Million | ▼ -31.8% |
| 2012 | 0.41x | CN¥169.25 Million | CN¥409.56 Million | ▲ +85.2% |
| 2011 | 0.22x | CN¥75.37 Million | CN¥337.70 Million | ▲ +728.6% |
| 2010 | -0.04x | CN¥-11.42 Million | CN¥321.68 Million | ▼ -106.3% |
| 2009 | 0.56x | CN¥216.11 Million | CN¥384.11 Million | ▲ +59.9% |
| 2008 | 0.35x | CN¥102.59 Million | CN¥291.46 Million | ▲ +1194.6% |
| 2007 | 0.03x | CN¥6.49 Million | CN¥238.53 Million | ▼ -91.0% |
| 2006 | 0.30x | CN¥75.27 Million | CN¥250.53 Million | ▼ -9.8% |
| 2005 | 0.33x | CN¥58.43 Million | CN¥175.45 Million | ▼ -19.6% |
| 2004 | 0.41x | CN¥54.19 Million | CN¥130.74 Million | ▼ -16.1% |
| 2003 | 0.49x | CN¥67.52 Million | CN¥136.61 Million | — |